Alligator Bioscience develops antibody-based pharmaceuticals for cancer treatment. The Company is specialized in the development of tumor-targeted immunotherapies, particularly agonistic mono- and bispecific antibodies, and is engaged in the early stages of drug development, from the idea stage to clinical phase II trials.

TypePublic
HQLund, SE
Founded2001
Size (employees)49 (est)+5%
Websitealligatorbioscience.se
Alligator Bioscience was founded in 2001 and is headquartered in Lund, SE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Alligator Bioscience Office Locations

Alligator Bioscience has an office in Lund
Lund, (HQ)
2 Scheelevägen
Show all (1)
Report incorrect company information

Alligator Bioscience Online and Social Media Presence

Embed Graph
Report incorrect company information

Alligator Bioscience News and Updates

Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015

LUND, Sweden, Dec. 11, 2018 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate...

Frontier - A Magazine about Alligator Bioscience and Immuno-oncology

STOCKHOLM, Dec 10, 2018 /PRNewswire/ -- The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator's research and development Read the full magazine through the link below. About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology...

Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

LUND, Sweden and SEATTLE, Nov. 9, 2018 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on...

Alligator Bioscience to Receive Million-dollar Payments - AbClon Partner Exercises Option

LUND, Sweden, Nov. 7, 2018 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than USD 3.5 million under its collaboration agreement with the South Korean company AbClon Inc. ("AbClon"). This is following the exercising of...

Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144

LUND, Sweden, Oct. 30, 2018 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announces that a new bispecific drug candidate, ATOR-1144, has entered preclinical...

Alligator Bioscience AB Interim Report January-September 2018

STOCKHOLM, Oct. 26, 2018 /PRNewswire/ -- The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator's research and development. Significant events July-September Preclinical development of ATOR-1015 completed. Application for Clinical Trial...
Report incorrect company information

Alligator Bioscience Blogs

Frontier – A Magazine about Alligator Bioscience and Immuno-oncology

The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator’s research and development Read the full magazine here. About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alliga…

Alligator Bioscience starts clinical phase I study with ATOR-1015

A first-in-class bispecific CTLA-4 antibody Inlägget Alligator Bioscience starts clinical phase I study with ATOR-1015 dök först upp på Alligator Bioscience.

Alligator Bioscience to receive million-dollar payments – AbClon partner exercises option

Lund, Sweden, November 7, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than USD 3.5 million under its collaboration agreement with the South Korean company AbClon Inc. (“AbClon”). This is following the exercising of an option by a third …

Nomination Committee appointed in respect of AGM 2019 in Alligator Bioscience AB

Lund, Sweden, November 6, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on May 9, 2019 has be…

Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144

New candidate drug selected – the bispecific tumor-localizing CTLA-4 x GITR antibody ATOR-1144 Inlägget Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144 dök först upp på Alligator Bioscience.

Alligator Bioscience receives government research grant

Lund, Sweden, October 5, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announced that they will receive a 500 000 SEK grant from Sweden’s government agency for innovation, Vinnova, f…
Show more

Alligator Bioscience Company Life and Culture

Report incorrect company information

Alligator Bioscience Frequently Asked Questions

  • When was Alligator Bioscience founded?

    Alligator Bioscience was founded in 2001.

  • How many employees does Alligator Bioscience have?

    Alligator Bioscience has 49 employees.

  • Who are Alligator Bioscience competitors?

    Competitors of Alligator Bioscience include Sareum Holdings, Akrevia Therapeutics and Karo Pharma.

  • Where is Alligator Bioscience headquarters?

    Alligator Bioscience headquarters is located at 2 Scheelevägen, Lund.

  • Where are Alligator Bioscience offices?

    Alligator Bioscience has an office in Lund.

  • How many offices does Alligator Bioscience have?

    Alligator Bioscience has 1 office.